# Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

> **NCT00006390** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** filgrastim
- **DRUG:** cyclophosphamide
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00006390
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07-05
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006390, "Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00006390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*